Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE Trial)

Aug 27, 2018

Overview : Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE): A Randomised, Double-blind, Placebo-controlled Trial Trial Reference Gaziano JM, Brotons C, Coppolecchia R, et al. Use of Aspirin to Reduce Risk... more

6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial

Mar 20, 2018

Overview : Trial Reference Hahn JY, Song YB, Oh JH, et al; SMART-DATE investigators. 6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial. Lancet. 2018 Mar 9.... more

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Sep 06, 2017

Overview : Trial Reference Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 Aug 27 [Epub ahead of print]. Abstract | Full Text   Expert Comment Pablo Avanzas,... more

CHAMPION-PHOENIX: A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention

Jul 17, 2014

Overview : The study randomized over 11,000 patients and the result showed that intravenous cangrelor cut the risk for periprocedural complications at all kinds of PCI compared with taking a pill of clopidogrel. Cangrelor's benefit of a 22% drop in a composite... more